SUBSTANTIATION AND FEATURES OF INTRODUCTION OF EXTERNAL REFERENCE PRICING TO THE PHARMACEUTICAL MARKET OF THE REPUBLIC OF BELARUS

  • Erchak A.I. Belarus State Economic University, Minsk, the Republic of Belarus
  • Mikulich I.M. Belarus State Economic University, Minsk, the Republic of Belarus
  • Gavrilenko V.A. Yaroslav-the-Wise Novgorod State University, Veliky Novgorod, Russia Saint-Petersburg University of State Fire Service of EMERCOM of Russia, Saint-Petersburg, Russia
  • Trofimova M.S. Yaroslav-the-Wise Novgorod State University, Veliky Novgorod, Russia

Abstract

The relevance of the regulation of the national pharmaceutical market is explained by its high social significance: the production and circulation of medicines have a direct impact on the national security and economic well-being of the country. The article reflects the results of studies in the field of administrative and economic mechanisms for regulating the market for medicines in connection with the need to ensure their availability. The authors identified the causes, opportunities and problems of introducing External Reference Pricing (ERP) in the Republic of Belarus, developed proposals to ensure a balanced consideration of the interests of the development of the national economy in the field of health and the needs of the poor in providing medicines. The proposed approach to price regulation of the national drug market (an external reference pricing tool as one of the ways to set restrictions when setting the maximum selling price for drugs), a mechanism for forming a ‘basket’ of reference countries, their inclusion criteria and assessment indicators, methods and methods for calculating limits price limits were implemented in the relevant regulatory acts adopted in the country in the field of regulation of the registration procedure and the pricing mechanism for oncological and cardiovascular drugs. When evaluating the effectiveness and efficiency of the developed mechanism, the problem field of application and specific features of the price regulation of the pharmaceutical market based on the external reference pricing in the Republic of Belarus were identified, and directions for solving the identified problems were worked out.

Keywords: external reference pricing; state regulation; Republic of Belarus; pharmaceutical market; pharmaceutical industry.

References

Cameron A., Hill S., Whyte P., Ramsey S. & Hedman L. WHO guideline on country pharmaceutical pricing policies. Geneva: World Health Organization, 2015.

EFPIA. The Pharmaceutical Industry in Figures (2017). Available at: https://www.efpia.eu/media/219735/efpia-pharmafigures2017_statisticbroch_v04-final.pdf (accessed 20.02.2020).

Ehtesham Sh. & Mansingh N. Conflicting interests in drug pricing: Innovation vs social need // Current Science (00113891). January 25, 2008. Vol. 94. Iss. 2. pp. 168-169.

Espin J., Rovira J. & De Labry A.O. WHO/HAI project on medicine prices and availability – Working paper 1: External reference pricing (2011). Available at: http://www.haiweb.org/medicineprices/24072012/ ERPfinalMay2011.pdf (accessed 13.02.2020).

European Parliament. Differences in costs of and access to pharmaceutical products in the EU. (2011). Available at: http://www.europarl.europa.eu/document/activities/cont/201201/20120130ATT36575/20120130ATT36575EN.pdf (accessed 10.02.2020).

Farmkompanii tratyat milliardy na razrabotku lekarstv dlya lecheniya redkih zabolevaniy [Pharmaceutical companies spend billions developing drugs to treat rare diseases] // Vedomosti. November 09, 2015 (In Russ.). Available at: https://www.vedomosti.ru/business/articles/2015/11/10/616116-farmkompanii-tratyat-milliardi-dollarov-razrabotku-lekarstv-dlya-lecheniya-redkih-zabolevanii (accessed 10.02.2020).

Gregson N., Sparrowhawk K., Mauskopf J. & Paul J. Pricing medicines: theory and practice. Challenges and opportunities // Nature Reviews. Drug Discovery. Vol. 4. February 2005. Iss. 2. pp. 121-130.

Kaiser U., Méndez S.J., Rønde Th. & Ullrich H. Regulation of Pharmaceutical Prices: Evidence from a reference price reform in Denmark // IZA DP. 2013. No. 7248. Available at: http://ftp.iza.org/dp7248.pdf (accessed 13.02.2020).

Lu Y., Hernandez P., Abegunde D. & Edejer T. The World Medicines Situation 2011. Medicine Expenditures / WHO/EMP/MIE/2011.2.6. Available at: https://www.who.int/health-accounts/documentation/world_medicine_situation.pdf (accessed 13.02.2020).

Nguyen T.A., Knight R.C., Roughead E.E., Brooks G. & Mant A. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries // Health Policy and Planning. 2015. No. 30. pp. 267-280. doi: 10.1093/heapol/czt105.

OECD health Policy Studies (2008). Pharmaceutical Pricing Policies in a Global Market. Available at: https://www.oecd.org/els/pharmaceutical-pricing-policies-in-a-global-market.htm (accessed 13.02.2020).

Prognoz razvitiya mirovogo farmatsevticheskogo rynka do 2018 goda [World Pharmaceutical Market Forecast 2018] (2015). Farmatsevticheskoe obozrenie Kazakhstana [Pharmaceutical review of Kazakhstan]. (In Russ.). Available at: https://www.pharm.reviews/analitika/item/42-prognoz-razvitiya-mirovogo-farmatsevticheskogo-rynka-do-2018 (accessed: 12.02.2020).

Rémuzat C., Urbinati D., Mzoughi O., Hammi E.E., Belgaied W. & Toumi M. Overview of external reference pricing systems in Europe // Journal of Market Access & Health Policy. 2015. No. 3. pp. 1-11. doi: 10.3402/jmahp.v3.27675.

Reyting stran mira po urovnyu rashodov na zdravoohranenie [Global ranking of health expenditure] (2019). Countries.World (In Russ.). Available at: http://ru.countries.world/world /Расходы на здравоохранение -5-129_590_215_a.html (accessed: 12.02.2020).

Rida N.M.A. & Mohamed I.M.I. Pricing strategies for pharmaceuticals in developing countries: what options do we have? // Generics and Biosimilars Initiative Journal. 2017. No. 6 (1). pp. 4-6. doi: 10.5639/gabij.2017.0601.002.

Stargardt T. & Schreyogg J. Impact of Cross-Reference Pricing on Pharmaceutical Prices // Applied Health Economics and Health Policy. 2006. No. 5. pp. 235-247. doi: 10.2165/00148365-200605040-00005.

Venkatachalam S. & Saberwal G. Bio-Business in Brief: A Case for New Drugs at Generic Prices from India // Current Science. 2012. No. 10. pp. 1375-1381. Available at: http://www.indiaenvironmentportal.org.in/ (accessed: 13.02.2020).

Keywords: external reference pricing; state regulation; Republic of Belarus; pharmaceutical market; pharmaceutical industry.

Authors

Aleksandr I. Erchak – PhD in Economics, Docent; Dean, Department of Commerce and Tourism, Belarus State Economic University, Minsk, the Republic of Belarus. E-mail: erchak_a@bseu.by. SPIN РИНЦ 4868-3504.
Inessa M. Mikulich – PhD in Economics, Docent; Head, Department of Trade and Services Economics, Belarus State Economic University, Minsk, the Republic of Belarus. E-mail: mikulich@bseu.by. SPIN РИНЦ 2803-3740.
Vladimir A. Gavrilenko – PhD in Law, Docent; Associate Professor, Department of Civil Law and Procedure, Yaroslav-the-Wise Novgorod State University, Veliky Novgorod, Russia; Associate Professor, Department of Theory and History of State and Law, Saint-Petersburg University of State Fire Service of EMERCOM of Russia, Saint-Petersburg, Russia. E-mail: gv22@mail.ru. SPIN РИНЦ 5093-5970.
Marina S. Trofimova – PhD in Law, Docent; Head, Department of Civil Law and Procedure, Yaroslav-the-Wise Novgorod State University, Veliky Novgorod, Russia. E-mail: Marina.Trofimova@novsu.ru. SPIN РИНЦ 7065-1903.

For citation:

Erchak A.I., Mikulich I.M., Gavrilenko V.A., Trofimova M.S. Substantiation and Features of Introduction of External Reference Pricing to the Pharmaceutical Market of the Republic of Belarus // BENEFICIUM. 2020. No. 2 (35). pp. 4-15. (In Russ.). DOI: http://doi.org/10.34680/BENEFICIUM.2020.2(35).4-15.

 

Published
2020-07-20
Issue
No 2 (2020)
Section
ISSUES OF TERRITORIAL AND SECTORAL DEVELOPMENT OF THE MODERN ECONONY